(VIANEWS) – STAAR Surgical Company (STAA), Dycom Industries (DY), Selective Insurance Group (SIGI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. STAAR Surgical Company (STAA)
19.4% sales growth and 5.57% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.38.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 87.89. Meaning, the purchaser of the share is investing $87.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
Volume
Today’s last reported volume for STAAR Surgical Company is 1043540 which is 27.51% above its average volume of 818353.
Moving Average
STAAR Surgical Company’s worth is below its 50-day moving average of $37.03 and way under its 200-day moving average of $50.54.
Earnings Before Interest, Taxes, Depreciation, and Amortization
STAAR Surgical Company’s EBITDA is 4.77.
2. Dycom Industries (DY)
16% sales growth and 23.04% return on equity
Dycom Industries, Inc. provides specialty contracting services in the United States. The company offers various specialty contracting services, including program management, engineering, construction, maintenance, and installation services, such as placement and splicing of fiber, copper, and coaxial cables to telecommunications providers. It also provides tower construction, lines and antenna installation, foundation and equipment pad construction, and small cell site placement for wireless carriers, as well as equipment installation and material fabrication, and site testing services; and installs and maintains customer premise equipment, such as digital video recorders, set top boxes, and modems for cable system operators. In addition, the company offers construction and maintenance services for electric and gas utilities, and other customers; and underground facility locating services, such as locating telephone, cable television, power, water, sewer, and gas lines for various utility companies, including telecommunication providers. Dycom Industries, Inc. was incorporated in 1969 and is headquartered in Palm Beach Gardens, Florida.
Earnings Per Share
As for profitability, Dycom Industries has a trailing twelve months EPS of $7.41.
PE Ratio
Dycom Industries has a trailing twelve months price to earnings ratio of 14.32. Meaning, the purchaser of the share is investing $14.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.04%.
Moving Average
Dycom Industries’s worth is way above its 50-day moving average of $87.73 and way higher than its 200-day moving average of $95.77.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Dycom Industries’s EBITDA is 1.
3. Selective Insurance Group (SIGI)
12.8% sales growth and 12.89% return on equity
Selective Insurance Group, Inc., together with its subsidiaries, provides insurance products and services in the United States. It operates through four segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. The company offers property insurance products, which covers the financial consequences of accidental loss of an insured's real property, personal property, and/or earnings due to the property's loss; and casualty insurance products that covers the financial consequences of employee injuries in the course of employment, and bodily injury and/or property damage to a third party, as well as flood insurance products. It also invests in fixed income investments and commercial mortgage loans, as well as equity securities and alternative investment portfolio. The company offers its insurance products and services to businesses, non-profit organizations, local government agencies, and individuals through independent retail agents and wholesale general agents. Selective Insurance Group, Inc. was founded in 1926 and is headquartered in Branchville, New Jersey.
Earnings Per Share
As for profitability, Selective Insurance Group has a trailing twelve months EPS of $5.21.
PE Ratio
Selective Insurance Group has a trailing twelve months price to earnings ratio of 19.4. Meaning, the purchaser of the share is investing $19.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.89%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Nov 13, 2023, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 1.38%.
4. Coca-Cola Consolidated (COKE)
11.7% sales growth and 35.46% return on equity
Coca-Cola Consolidated, Inc., together with its subsidiaries, manufactures, markets, and distributes nonalcoholic beverages primarily products of The Coca-Cola Company in the United States. The company offers sparkling beverages, such as sparling beverages; and still beverages, including energy products, as well as noncarbonated beverages comprising bottled water, ready to drink coffee and tea, enhanced water, juices, and sports drinks. It also sells its products to other Coca-Cola bottlers; and post-mix products that are dispensed through equipment, which mixes the fountain syrup with carbonated or still water enabling fountain retailers to sell finished products to consumers in cups or glasses. In addition, the company distributes products for various other beverage brands that include Dr Pepper and Monster Energy. It sells and distributes its products directly to grocery stores, mass merchandise stores, club stores, convenience stores, and drug stores; and restaurants, schools, amusement parks, and recreational facilities, as well as through vending machine outlets. The company was formerly known as Coca-Cola Bottling Co. Consolidated and changed its name to Coca-Cola Consolidated, Inc. in January 2019. Coca-Cola Consolidated, Inc. was incorporated in 1980 and is headquartered in Charlotte, North Carolina.
Earnings Per Share
As for profitability, Coca-Cola Consolidated has a trailing twelve months EPS of $48.03.
PE Ratio
Coca-Cola Consolidated has a trailing twelve months price to earnings ratio of 18.37. Meaning, the purchaser of the share is investing $18.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.46%.
Sales Growth
Coca-Cola Consolidated’s sales growth is 11.3% for the ongoing quarter and 11.7% for the next.
5. FirstCash (FCFS)
9.2% sales growth and 12.35% return on equity
FirstCash Holdings, Inc, together with its subsidiaries, operates retail pawn stores in the United States, Mexico, and rest of Latin America. Its pawn stores lend money on the collateral of pledged personal property, including jewelry, electronics, tools, appliances, sporting goods, and musical instruments; and retails merchandise acquired through collateral forfeitures on forfeited pawn loans and over-the-counter purchases of merchandise directly from customers. The company is also involved in melting scrap jewelry, as well as sells gold, silver, and diamonds in commodity markets. As of December 31, 2021, it operated 1,081 stores in the United States and the District of Columbia; 1,656 stores in Mexico; 60 stores in Guatemala; 13 stores in El Salvador; and 15 stores in Colombia. The company was incorporated in 1988 and is headquartered in Fort Worth, Texas.
Earnings Per Share
As for profitability, FirstCash has a trailing twelve months EPS of $4.99.
PE Ratio
FirstCash has a trailing twelve months price to earnings ratio of 22.74. Meaning, the purchaser of the share is investing $22.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.35%.
Moving Average
FirstCash’s worth is higher than its 50-day moving average of $107.05 and way higher than its 200-day moving average of $98.06.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17%, now sitting on 3.05B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FirstCash’s EBITDA is 2.27.
6. STERIS (STE)
5.3% sales growth and 9.17% return on equity
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Earnings Per Share
As for profitability, STERIS has a trailing twelve months EPS of $5.51.
PE Ratio
STERIS has a trailing twelve months price to earnings ratio of 38.35. Meaning, the purchaser of the share is investing $38.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.17%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 7.4% and 7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 5.23B for the twelve trailing months.
Moving Average
STERIS’s value is under its 50-day moving average of $212.99 and above its 200-day moving average of $208.47.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 19, 2023, the estimated forward annual dividend rate is 2.08 and the estimated forward annual dividend yield is 1.02%.
